达格列净应用慢性肾脏病治疗研究进展

Research Progress on the Application of Dapagliflozin in the Treatment of Chronic Kidney Disease

目前,慢性肾脏病已成为全球严峻的健康挑战,其患病率和死亡率持续攀升。在我国,慢性肾脏病患者数量众多,然而可用的治疗手段却相对有限。近期研究指出,达格列净不仅是一种出色的血糖调节药物,同时可以降低心血管不良事件的发生风险,并能推迟糖尿病肾脏疾病的进展。在非糖尿病肾脏病的慢性肾脏病患者中也观察到肾脏获益。本文系统性地总结了达格列净在慢性肾脏病治疗中的最新研究进展和临床应用现状,对达格列净对慢性肾脏病患者的治疗策略、用药原则和潜在效果提供了理论基础,推动达格列净在慢性肾脏病中的进一步应用和开发。

At present, chronic kidney disease (CKD) is a serious global health problem, and its morbidity and mortality are increasing. There are many patients in our country, and the means of treatment are limited. Recently, it has been found that dapagliflozin is not only a good hypoglycemic drug, but also can reduce cardiovascular adverse events and delay the onset of diabetic nephropathy (DN). Renal benefits have also been observed in patients with non-diabetic nephropathy. This article systemat-ically summarizes the latest research progress and clinical application status of dapagliflozin in the treatment of chronic kidney disease, provides a theoretical basis for the treatment strategy, medi-cation principles and potential effects of dapagliflozin in patients with chronic kidney disease, thereby advancing further application and development in the field of chronic kidney disease.